Nicox (XPAR:ALCOX) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 09, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Nicox EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Nicox (XPAR:ALCOX) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Nicox EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Nicox's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (XPAR:ALCOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

NICXF:USA NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (XPAR:ALCOX) Headlines

No Headlines